EU approves Astrazeneca's Enhertu for HER2 positive metastatic solid tumors
Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that Enhertu (trastuzumab deruxtecan) has been approved in the European Union as monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (IHC 3+) solid tumors who have received prior treatment and who have no satisfactory alternative treatment options.




-2-640x360.webp&w=3840&q=75)





